LONDON – There's no resting on the laurels at Heptares Therapeutics Ltd., which on Monday announced a potential $1.89 billion plus royalties deal with Pfizer Inc. in multiple indications, as a main course to follow last week's $410 million migraine agreement with Teva Pharmaceutical Industries Ltd.